Trial Profile

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition

Status: Suspended

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy-StemCyte (Primary)
Indications Post acute COVID 19 syndrome
Focus Expanded access; Therapeutic Use
Sponsors StemCyte

Most Recent Events

26 Jan 2026 According to a StemCyte media release, the U.S. Food and Drug Administration (FDA) has cleared an Expanded Access (EA) program for RegeneCyte, the company's FDA-licensed hematopoietic progenitor cell (HPC) therapy.
21 Jan 2026 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com